Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group (TCOG) GI-1601 study

BACKGROUND: Capecitabine plus oxaliplatin (CapeOX) is a standard treatment option for advanced gastric cancer (AGC). We conducted a prospective multicenter phase II study to evaluate the efficacy and safety of CapeOX as a first-line therapy for AGC in older patients. METHODS: Chemotherapy-naive pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawabata, Ryohei, Chin, Keisho, Takahari, Daisuke, Hosaka, Hisashi, Muto, Osamu, Shindo, Yoshiaki, Nagata, Naoki, Yabusaki, Hiroshi, Imamura, Hiroshi, Endo, Shunji, Kashiwada, Tomomi, Nakamura, Masato, Hihara, Jun, Kobayashi, Michiya, Sagawa, Tamotsu, Saito, Soh, Sato, Atsushi, Yamada, Takeshi, Okano, Naohiro, Shimada, Ken, Matsushima, Masashi, Kataoka, Masato, Matsumoto, Shigemi, Goto, Masahiro, Kotaka, Masahito, Shiraishi, Takeshi, Yamai, Hiromichi, Nagashima, Fumio, Ishizuka, Naoki, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640487/
https://www.ncbi.nlm.nih.gov/pubmed/37610558
http://dx.doi.org/10.1007/s10120-023-01423-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640487/
https://www.ncbi.nlm.nih.gov/pubmed/37610558
http://dx.doi.org/10.1007/s10120-023-01423-z

Ejemplares similares